These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 25596739)

  • 1. The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.
    Ehrhardt M; Craveiro RB; Holst MI; Pietsch T; Dilloo D
    Oncotarget; 2015 Jan; 6(2):802-13. PubMed ID: 25596739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The anti-neoplastic activity of Vandetanib against high-risk medulloblastoma variants is profoundly enhanced by additional PI3K inhibition.
    Craveiro RB; Ehrhardt M; Velz J; Olschewski M; Goetz B; Pietsch T; Dilloo D
    Oncotarget; 2017 Jul; 8(29):46915-46927. PubMed ID: 28159923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The PI3K inhibitor GDC-0941 combines with existing clinical regimens for superior activity in multiple myeloma.
    Munugalavadla V; Mariathasan S; Slaga D; Du C; Berry L; Del Rosario G; Yan Y; Boe M; Sun L; Friedman LS; Chesi M; Leif Bergsagel P; Ebens A
    Oncogene; 2014 Jan; 33(3):316-25. PubMed ID: 23318440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FDA approved PI3K inhibitor GDC-0941 enhances in vitro the anti-neoplastic efficacy of Axitinib against c-myc-amplified high-risk medulloblastoma.
    Ehrhardt M; Craveiro RB; Velz J; Olschewski M; Casati A; Schönberger S; Pietsch T; Dilloo D
    J Cell Mol Med; 2018 Apr; 22(4):2153-2161. PubMed ID: 29377550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In comparative analysis of multi-kinase inhibitors for targeted medulloblastoma therapy pazopanib exhibits promising in vitro and in vivo efficacy.
    Craveiro RB; Ehrhardt M; Holst MI; Pietsch T; Dilloo D
    Oncotarget; 2014 Aug; 5(16):7149-61. PubMed ID: 25216529
    [TBL] [Abstract][Full Text] [Related]  

  • 6. More antitumor efficacy of the PI3K inhibitor GDC-0941 in breast cancer with PIK3CA mutation or HER2 amplification status in vitro.
    Zheng J; Wang H; Yao J; Zou X
    Pharmazie; 2014 Jan; 69(1):38-42. PubMed ID: 24601221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GDC-0941, a novel class I selective PI3K inhibitor, enhances the efficacy of docetaxel in human breast cancer models by increasing cell death in vitro and in vivo.
    Wallin JJ; Guan J; Prior WW; Lee LB; Berry L; Belmont LD; Koeppen H; Belvin M; Friedman LS; Sampath D
    Clin Cancer Res; 2012 Jul; 18(14):3901-11. PubMed ID: 22586300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.
    Singh AR; Joshi S; Zulcic M; Alcaraz M; Garlich JR; Morales GA; Cho YJ; Bao L; Levy ML; Newbury R; Malicki D; Messer K; Crawford J; Durden DL
    PLoS One; 2016; 11(3):e0150836. PubMed ID: 26938241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ellagic Acid Enhances the Efficacy of PI3K Inhibitor GDC-0941 in Breast Cancer Cells.
    Shi L; Gao X; Li X; Jiang N; Luo F; Gu C; Chen M; Cheng H; Liu P
    Curr Mol Med; 2015; 15(5):478-86. PubMed ID: 25941816
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The antitumor effect of GDC-0941 alone and in combination with rapamycin in breast cancer cells.
    Zheng J; Zou X; Yao J
    Chemotherapy; 2012; 58(4):273-81. PubMed ID: 23006739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The alkylphospholipid perifosine induces apoptosis and p21-mediated cell cycle arrest in medulloblastoma.
    Kumar A; Fillmore HL; Kadian R; Broaddus WC; Tye GW; Van Meter TE
    Mol Cancer Res; 2009 Nov; 7(11):1813-21. PubMed ID: 19887560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic-pharmacodynamic modeling of tumor growth inhibition and biomarker modulation by the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.
    Salphati L; Wong H; Belvin M; Bradford D; Edgar KA; Prior WW; Sampath D; Wallin JJ
    Drug Metab Dispos; 2010 Sep; 38(9):1436-42. PubMed ID: 20538720
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.
    Dijkgraaf GJ; Alicke B; Weinmann L; Januario T; West K; Modrusan Z; Burdick D; Goldsmith R; Robarge K; Sutherlin D; Scales SJ; Gould SE; Yauch RL; de Sauvage FJ
    Cancer Res; 2011 Jan; 71(2):435-44. PubMed ID: 21123452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts.
    Shu Q; Antalffy B; Su JM; Adesina A; Ou CN; Pietsch T; Blaney SM; Lau CC; Li XN
    Clin Cancer Res; 2006 Aug; 12(15):4687-94. PubMed ID: 16899619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intermittent administration of MEK inhibitor GDC-0973 plus PI3K inhibitor GDC-0941 triggers robust apoptosis and tumor growth inhibition.
    Hoeflich KP; Merchant M; Orr C; Chan J; Den Otter D; Berry L; Kasman I; Koeppen H; Rice K; Yang NY; Engst S; Johnston S; Friedman LS; Belvin M
    Cancer Res; 2012 Jan; 72(1):210-9. PubMed ID: 22084396
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive biomarkers of sensitivity to the phosphatidylinositol 3' kinase inhibitor GDC-0941 in breast cancer preclinical models.
    O'Brien C; Wallin JJ; Sampath D; GuhaThakurta D; Savage H; Punnoose EA; Guan J; Berry L; Prior WW; Amler LC; Belvin M; Friedman LS; Lackner MR
    Clin Cancer Res; 2010 Jul; 16(14):3670-83. PubMed ID: 20453058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small-molecule inhibitors of phosphatidylinositol 3-kinase/Akt signaling inhibit Wnt/beta-catenin pathway cross-talk and suppress medulloblastoma growth.
    Baryawno N; Sveinbjörnsson B; Eksborg S; Chen CS; Kogner P; Johnsen JI
    Cancer Res; 2010 Jan; 70(1):266-76. PubMed ID: 20028853
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.
    Faria CC; Golbourn BJ; Dubuc AM; Remke M; Diaz RJ; Agnihotri S; Luck A; Sabha N; Olsen S; Wu X; Garzia L; Ramaswamy V; Mack SC; Wang X; Leadley M; Reynaud D; Ermini L; Post M; Northcott PA; Pfister SM; Croul SE; Kool M; Korshunov A; Smith CA; Taylor MD; Rutka JT
    Cancer Res; 2015 Jan; 75(1):134-46. PubMed ID: 25391241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PI3K/mTOR signaling pathways in medulloblastoma.
    Mohan AL; Friedman MD; Ormond DR; Tobias M; Murali R; Jhanwar-Uniyal M
    Anticancer Res; 2012 Aug; 32(8):3141-6. PubMed ID: 22843885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GDC-0941 sensitizes breast cancer to ABT-737 in vitro and in vivo through promoting the degradation of Mcl-1.
    Zheng L; Yang W; Zhang C; Ding WJ; Zhu H; Lin NM; Wu HH; He QJ; Yang B
    Cancer Lett; 2011 Oct; 309(1):27-36. PubMed ID: 21664043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.